Lentigen raises seed, series A financing, plans to add commercial-scale manufacturing

By E. Janene Geiss

Philadelphia, Nov. 30 - Lentigen Corp. said Wednesday that it raised an undisclosed amount of seed and series A financing.

Greenwich Biotech Ventures was the investor. Terms of the financing have not been disclosed.

The company said it will use the funding to launch its current programs, add commercial-scale manufacturing capabilities and increase the company's infrastructure.

As part of the financing, Greenwich managing partner David Wetherell has been appointed chairman of the company's board of directors.

"We believe that the company's lentiviral vector technology has the potential to make a significant impact on the biotechnology industry by providing an efficient, stable and safe mechanism for the delivery of genes into cells for the treatment and vaccination of serious diseases," Wetherell said in a company news release.

Lentigen is a Baltimore biotechnology company focused on the manufacturing and development of lentiviral vectors using its proprietary gene delivery technology.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.